Predicting LACSC Recurrence with SCC

Although serum squamous cell carcinoma (SCC) antigen values are known to be useful in predicting the prognosis of cervical SCC, they have only been examined in a cursory manner.

Yusuke Yamaoka and the team aimed to meticulously investigate the clinical significance of serum SCC antigen levels in patients with locally advanced cervical squamous cell carcinoma (LACSC).

They performed an inclusive analysis involving patients diagnosed with the local stage (T-stage) 1b3/2/3 LACSC who underwent initial treatment at the institute between January 2006 and December 2016 (T-1b3: n=30; T-2: n=75; T-3: n=34). Patients were categorized into three groups based on pre-treatment SCC values, and differences in clinical background, laboratory and pathology findings, and prognosis were examined.

About the SCC distribution, no significant difference was observed among the T-1b3/2/3 cases with elevated SCC levels. In stages T-1b3, T-2, and T-3, most recurrences in the SCC-High group were distant (T-1b3: 3 out of 5 recurrences; T-2: 6 out of 7 recurrences; T-3: 4 out of 8 recurrences), while most recurrences in the SCC-Low group were pelvic (T-1b3: 2 out of 3 recurrences; T-2: 8 out of 8 recurrences; T-3: 3 out of 3 recurrences).

The study concluded that in LACSC, serum SCC antigen levels before treatment strongly correlate with the recurrence site. Patients with low levels should be closely monitored for local recurrence, while those with high levels warrant vigilance for distant recurrence.

No funding information was given.

Source: https://pubmed.ncbi.nlm.nih.gov/38677756/

Yamaoka Y, Tamura S, Yamanoi K, et al. (2024). “Clinical Significance of Serum SCC Levels Before Treatment for Locally Advanced Cervical Squamous Cell Carcinoma.” Anticancer Res. 2024 May;44(5):2009-2019. doi: 10.21873/anticanres.17004. PMID: 38677756.